Palvella Therapeutics, Inc.   Report issue

For profit Phase 3
Founded: Wayne PA United States (2015)
Status: No NME R&D (2015)

Organization Overview

First Clinical Trial
2019
NCT03920228
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Palvella Therapeutics, Inc.

Active Ingredients

Drugs in Phase 3 Trials (1)

rapamycin (6 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Nails, Malformed (Phase 3)

Pachyonychia Congenita (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 6
  • # of Trial APIs: 1